A Voldsgaard1, P Bager2, E Garde3, P Åkeson3, A M Leffers3, C G Madsen3, C Kapel4, A Roepstorff5, S M Thamsborg4, M Melbye2, H Siebner3, H B Søndergaard1, F Sellebjerg1, P Soelberg Sørensen6. 1. Danish Multiple Sclerosis Center, Copenhagen University Hospital, Denmark. 2. Department of Epidemiology Research, Statens Serum Institut, Denmark. 3. Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital, Denmark. 4. Faculty of Life Sciences, University of Copenhagen, Denmark. 5. Faculty of Life Sciences, University of Copenhagen, Denmark/Deceased. 6. Danish Multiple Sclerosis Center, Copenhagen University Hospital, Denmark pss@rh.dk.
Abstract
BACKGROUND: An observational study has suggested that relapsing-remitting multiple sclerosis patients with helminth infections have lower disease activity and progression than uninfected multiple sclerosis patients. OBJECTIVE: To evaluate the safety and efficacy on MRI activity of treatment with TSO in relapsing MS. METHODS: The study was an open-label, magnetic resonance imaging assessor-blinded, baseline-to-treatment study including ten patients with relapsing forms of multiple sclerosis. Median (range) age was 41 (24-55) years, disease duration 9 (4-34) years, Expanded Disability Status Scale score 2.5 (1-5.0), and number of relapses within the last two years 3 (2-5). Four patients received no disease modifying therapy, while six patients received IFN-β. After an observational period of 8 weeks, patients received 2500 ova from the helminth Trichuris suis orally every second week for 12 weeks. Patients were followed with serial magnetic resonance imaging, neurological examinations, laboratory safety tests and expression of immunological biomarker genes. RESULTS: Treatment with Trichuris suis orally was well-tolerated apart from some gastrointestinal symptoms. Magnetic resonance imaging revealed 6 new or enlarged T2 lesions in the run-in period, 7 lesions in the early period and 21 lesions in the late treatment period. Two patients suffered a relapse before treatment and two during treatment. Eight patients developed eosinophilia. The expression of cytokines and transcription factors did not change. CONCLUSIONS: In a small group of relapsing multiple sclerosis patients, Trichuris suis oral therapy was well tolerated but without beneficial effect.
BACKGROUND: An observational study has suggested that relapsing-remitting multiple sclerosispatients with helminth infections have lower disease activity and progression than uninfected multiple sclerosispatients. OBJECTIVE: To evaluate the safety and efficacy on MRI activity of treatment with TSO in relapsing MS. METHODS: The study was an open-label, magnetic resonance imaging assessor-blinded, baseline-to-treatment study including ten patients with relapsing forms of multiple sclerosis. Median (range) age was 41 (24-55) years, disease duration 9 (4-34) years, Expanded Disability Status Scale score 2.5 (1-5.0), and number of relapses within the last two years 3 (2-5). Four patients received no disease modifying therapy, while six patients received IFN-β. After an observational period of 8 weeks, patients received 2500 ova from the helminth Trichuris suis orally every second week for 12 weeks. Patients were followed with serial magnetic resonance imaging, neurological examinations, laboratory safety tests and expression of immunological biomarker genes. RESULTS: Treatment with Trichuris suis orally was well-tolerated apart from some gastrointestinal symptoms. Magnetic resonance imaging revealed 6 new or enlarged T2 lesions in the run-in period, 7 lesions in the early period and 21 lesions in the late treatment period. Two patients suffered a relapse before treatment and two during treatment. Eight patients developed eosinophilia. The expression of cytokines and transcription factors did not change. CONCLUSIONS: In a small group of relapsing multiple sclerosispatients, Trichuris suis oral therapy was well tolerated but without beneficial effect.
Authors: Andrew R Williams; Elsenoor J Klaver; Lisa C Laan; Aina Ramsay; Christos Fryganas; Rolf Difborg; Helene Kringel; Jess D Reed; Irene Mueller-Harvey; Søren Skov; Irma van Die; Stig M Thamsborg Journal: Immunology Date: 2016-11-30 Impact factor: 7.397
Authors: John Fleming; Gianna Hernandez; Leslie Hartman; Jane Maksimovic; Sara Nace; Benjamin Lawler; Todd Risa; Thomas Cook; Rashmi Agni; Mark Reichelderfer; Christopher Luzzio; Loren Rolak; Aaron Field; Zsuzsanna Fabry Journal: Mult Scler Date: 2017-10-24 Impact factor: 6.312
Authors: Radu Tanasescu; Christopher R Tench; Cris S Constantinescu; Gary Telford; Sonika Singh; Nanci Frakich; David Onion; Dorothee P Auer; Bruno Gran; Nikos Evangelou; Yasser Falah; Colin Ranshaw; Cinzia Cantacessi; Timothy P Jenkins; David I Pritchard Journal: JAMA Neurol Date: 2020-09-01 Impact factor: 18.302
Authors: Bonnie Douglas; Oyebola Oyesola; Martha M Cooper; Avery Posey; Elia Tait Wojno; Paul R Giacomin; De'Broski R Herbert Journal: Annu Rev Immunol Date: 2021-03-01 Impact factor: 28.527
Authors: Ivet A Yordanova; Friederike Ebner; Axel Ronald Schulz; Svenja Steinfelder; Berit Rosche; Anna Bolze; Friedemann Paul; Henrik E Mei; Susanne Hartmann Journal: Life (Basel) Date: 2021-01-29